verapamil has been researched along with Proteinuria in 29 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effect of fixed-dose trandolapril-verapamil (FDTV) with that of trandolapril on proteinuria in normotensive, type 2 diabetic patients." | 9.11 | The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. ( Arceo-Navarro, A; Gomez-Harper, CT; Lozano-Nuevo, JJ; Rodriguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G, 2004) |
| " In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure." | 7.70 | Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998) |
| "The calcium antagonist verapamil was infused intravenously in 10 patients with severe postpartum gestational proteinuric hypertension." | 7.67 | Verapamil in the treatment of severe postpartum hypertension. ( Belfort, MA; Moore, PJ, 1988) |
| " We hypothesized that a trandolapril/verapamil SR (T/V) fixed-dose combination (FDC) was superior to a benazepril/amlodipine (B/A) FDC for reducing albuminuria in 304 hypertensive diabetic nephropathy patients when treated for 36 weeks." | 5.13 | Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. ( Bacher, P; Champion, A; Fakouhi, K; Tian, M; Toto, RD, 2008) |
| "To compare the effect of fixed-dose trandolapril-verapamil (FDTV) with that of trandolapril on proteinuria in normotensive, type 2 diabetic patients." | 5.11 | The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. ( Arceo-Navarro, A; Gomez-Harper, CT; Lozano-Nuevo, JJ; Rodriguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G, 2004) |
| "We tested whether the combination of verapamil (V) or amlodipine (A) with trandolapril (T) affected proteinuria differently from T alone in patients with nondiabetic nephropathies." | 5.10 | The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. ( Berto, IM; Boero, R; Lanfranco, G; Massara, C; Perosa, P; Quarello, F; Rollino, C; Vagelli, G, 2003) |
| " Only angiotensin-converting enzyme inhibitor (trandolapril) treatment, alone or better combined with verapamil, reduces proteinuria and increases serum albumin." | 5.10 | Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. ( , 2002) |
| "Non-dihydropyridine calcium antagonists such as verapamil are equally effective in reducing proteinuria as ACE inhibitors in hypertensive patients with diabetic nephropathy." | 5.09 | Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. ( de Jong, PE; de Zeeuw, D; Hemmelder, MH, 1999) |
| " There were no differences in the BP reached in the four therapy groups; however, proteinuria only decreased in the patients treated with trandolapril alone or in combination with verapamil." | 5.09 | Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs. ( Dall'Anese, C; García de Vinuesa, S; Gómez-Campderá, F; Luño, J; Ridao, N; Sánchez, M; Valderrábano, F, 2001) |
| "The present randomized, open label, parallel group designed study tests the hypothesis that, at similar levels of blood pressure, the combination of an ACE inhibitor, trandolapril (T) with the non-DHPCA, verapamil (V) produces a greater reduction in proteinuria over either agent alone at one year." | 5.08 | Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. ( Bakris, GL; DeQuattro, V; McMahon, FG; Weir, MR, 1998) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| " In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure." | 3.70 | Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998) |
| "The calcium antagonist verapamil has been demonstrated to be effective in reducing hypertension in patients in whom sodium intake was not restricted." | 3.68 | The antihypertensive effect of verapamil in patients with chronic renal failure. ( Alcazar, JM; Rodicio, JL; Ruilope, LM, 1992) |
| "The effect of long-term treatment with either enalapril or high dose verapamil on survival, proteinuria, blood pressure and renal morphology was studied in female Wistar rats with markedly reduced renal mass." | 3.67 | Long-term enalapril and verapamil in rats with reduced renal mass. ( Bock, HA; Brunner, FP; Hermle, M; Mihatsch, MJ; Thiel, G, 1989) |
| "The calcium antagonist verapamil was infused intravenously in 10 patients with severe postpartum gestational proteinuric hypertension." | 3.67 | Verapamil in the treatment of severe postpartum hypertension. ( Belfort, MA; Moore, PJ, 1988) |
| "Renal hemodynamics, albuminuria and metabolic parameters were evaluated for a period of one year." | 2.67 | Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. ( Bakris, GL; Barnhill, BW; Sadler, R, 1992) |
| "In hypertensive patients with NIDDM, a diuretic-free therapy based on the Ca2+ antagonist verapamil and/or the ACE inhibitor enalapril can effectively decrease blood pressure without adversely affecting carbohydrate and lipid metabolism." | 2.67 | Antihypertensive therapy with Ca2+. Antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. ( Beretta-Piccoli, C; Ferrari, P; Ferrier, C; Keller, U; Riesen, WF; Weidmann, P, 1991) |
| " The aim of this study was to determine whether these inhibitors can prevent the toxic effects of Cd on the kidney which is the critical organ." | 1.30 | Effect of calmodulin-inhibitors and verapamil on the nephrotoxicity of cadmium in rat. ( Bernard, A; Lermioglu, F, 1998) |
| "Verapamil was given to the animals in Group I for 5 days starting 1 day before shockwave exposure." | 1.29 | Verapamil limits shockwave-induced renal tubular damage in vivo. ( Abelius, A; Bichler, KH; Billes, I; Grossmann, T; Strohmaier, WL; Wilbert, DM, 1994) |
| "Enalapril treatment (5 mg/kg/day, n = 11) or felodipine (30 mg/kg/day, n = 11) reduced systolic blood pressure to a comparable degree." | 1.27 | Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat. ( Cubela, R; Debrevi, L; Jackson, B; Johnston, CI; Whitty, M, 1987) |
| "Treatment with enalapril reduced the degree of proteinuria at three months (36." | 1.27 | Diabetic nephropathy in the rat: differing renal effects of an angiotensin converting enzyme inhibitor and a calcium inhibitor. ( Jackson, B; Whitty, MR, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (20.69) | 18.7374 |
| 1990's | 14 (48.28) | 18.2507 |
| 2000's | 6 (20.69) | 29.6817 |
| 2010's | 3 (10.34) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hammoud, SH | 1 |
| Alkhansa, S | 1 |
| Mahjoub, N | 1 |
| Omar, AG | 1 |
| El-Mas, MM | 1 |
| Eid, AA | 1 |
| Cove-Smith, A | 1 |
| Mulgrew, CJ | 1 |
| Rudyk, O | 1 |
| Dutt, N | 1 |
| McLatchie, LM | 1 |
| Shattock, MJ | 1 |
| Hendry, BM | 1 |
| Albayrak, B | 1 |
| Cankaya, E | 1 |
| Cetinkaya, R | 1 |
| Cerrah, S | 1 |
| Bilen, Y | 1 |
| Toto, RD | 1 |
| Tian, M | 1 |
| Fakouhi, K | 1 |
| Champion, A | 1 |
| Bacher, P | 1 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Boero, R | 1 |
| Rollino, C | 1 |
| Massara, C | 1 |
| Berto, IM | 1 |
| Perosa, P | 1 |
| Vagelli, G | 1 |
| Lanfranco, G | 1 |
| Quarello, F | 1 |
| Rubio-Guerra, AF | 1 |
| Arceo-Navarro, A | 1 |
| Vargas-Ayala, G | 1 |
| Rodriguez-Lopez, L | 1 |
| Lozano-Nuevo, JJ | 1 |
| Gomez-Harper, CT | 1 |
| Elliott, WJ | 1 |
| Strohmaier, WL | 1 |
| Abelius, A | 1 |
| Billes, I | 1 |
| Grossmann, T | 1 |
| Wilbert, DM | 1 |
| Bichler, KH | 1 |
| Cohen, EP | 1 |
| Moulder, JE | 1 |
| Fish, BL | 1 |
| Hill, P | 1 |
| August, P | 1 |
| Lenz, T | 1 |
| Laragh, JH | 1 |
| Münter, K | 1 |
| Hergenröder, S | 1 |
| Jochims, K | 1 |
| Kirchengast, M | 1 |
| Lermioglu, F | 1 |
| Bernard, A | 1 |
| Bakris, GL | 3 |
| Weir, MR | 1 |
| DeQuattro, V | 1 |
| McMahon, FG | 1 |
| Yoneda, H | 1 |
| Toriumi, W | 1 |
| Ohmachi, Y | 1 |
| Okumura, F | 1 |
| Fujimura, H | 1 |
| Nishiyama, S | 1 |
| Hemmelder, MH | 1 |
| de Zeeuw, D | 1 |
| de Jong, PE | 1 |
| Griffin, KA | 1 |
| Picken, MM | 1 |
| Bidani, AK | 1 |
| García de Vinuesa, S | 1 |
| Luño, J | 1 |
| Gómez-Campderá, F | 1 |
| Ridao, N | 1 |
| Sánchez, M | 1 |
| Dall'Anese, C | 1 |
| Valderrábano, F | 1 |
| Rodicio, JL | 1 |
| Alcazar, JM | 1 |
| Ruilope, LM | 1 |
| Barnhill, BW | 1 |
| Sadler, R | 1 |
| Ferrier, C | 1 |
| Ferrari, P | 1 |
| Weidmann, P | 1 |
| Keller, U | 1 |
| Beretta-Piccoli, C | 1 |
| Riesen, WF | 1 |
| Brunner, FP | 2 |
| Bock, HA | 2 |
| Hermle, M | 2 |
| Thiel, G | 2 |
| Mihatsch, MJ | 2 |
| Jackson, B | 2 |
| Cubela, R | 1 |
| Debrevi, L | 1 |
| Whitty, M | 1 |
| Johnston, CI | 1 |
| Whitty, MR | 1 |
| Ploeg, RJ | 1 |
| Vreugdenhil, P | 1 |
| Goossens, D | 1 |
| McAnulty, JF | 1 |
| Southard, JH | 1 |
| Belzer, FO | 1 |
| Yoshioka, T | 1 |
| Shiraga, H | 1 |
| Yoshida, Y | 1 |
| Fogo, A | 1 |
| Glick, AD | 1 |
| Deen, WM | 1 |
| Hoyer, JR | 1 |
| Ichikawa, I | 1 |
| Belfort, MA | 1 |
| Moore, PJ | 1 |
1 review available for verapamil and Proteinuria
| Article | Year |
|---|---|
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
9 trials available for verapamil and Proteinuria
| Article | Year |
|---|---|
Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2008 |
The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Double- | 2003 |
The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Body Weight; Calcium Channe | 2004 |
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Diabetes M | 1998 |
Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Cross-Ove | 1999 |
Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2001 |
Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium; C | 2002 |
Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; | 1992 |
Antihypertensive therapy with Ca2+. Antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enalapril; Fema | 1991 |
19 other studies available for verapamil and Proteinuria
| Article | Year |
|---|---|
Molecular basis of the counteraction by calcium channel blockers of cyclosporine nephrotoxicity.
Topics: Animals; Biomarkers; Blood Urea Nitrogen; Calcium Channel Blockers; Collagen Type IV; Creatinine; Cy | 2018 |
Anti-proliferative actions of T-type calcium channel inhibition in Thy1 nephritis.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Calcium Channels, T-Type; Creatinine; Dose-Respon | 2013 |
The effects of dual and triple combinations of trandolapril, telmisartan, and verapamil on overt proteinuria in the patients with diabetic nephropathy.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood | 2016 |
An individualized approach to the hypertensive patient with renal disease: six illustrative case studies.
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arterial Occlusive Dis | 1995 |
Verapamil limits shockwave-induced renal tubular damage in vivo.
Topics: Animals; Diuresis; Hematuria; Kidney Tubules; Lithotripsy; Male; Proteinuria; Rats; Rats, Wistar; Va | 1994 |
Prophylaxis of experimental bone marrow transplant nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Bone Mar | 1994 |
Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure.
Topics: Amlodipine; Antihypertensive Agents; Dipeptides; Hemodynamics; Humans; Kidney Failure, Chronic; Lisi | 1993 |
Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke-prone rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Calcium | 1996 |
Effect of calmodulin-inhibitors and verapamil on the nephrotoxicity of cadmium in rat.
Topics: Animals; Cadmium Chloride; Calcium Channel Blockers; Calmodulin; Chlorpromazine; Dopamine Antagonist | 1998 |
Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats.
Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; B | 1998 |
Class differences in the effects of calcium channel blockers in the rat remnant kidney model.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Diltiazem; Disease Models, Animal; Drinking; Felo | 1999 |
The antihypertensive effect of verapamil in patients with chronic renal failure.
Topics: Antihypertensive Agents; Diet, Sodium-Restricted; Dietary Proteins; Humans; Hypertension; Kidney Fai | 1992 |
Control of hypertension by verapamil enhances renal damage in a rat remnant kidney model.
Topics: Animals; Blood Pressure; Female; Hypertension; Kidney; Nephrectomy; Organ Size; Proteinuria; Rats; R | 1991 |
Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Diabetes Mellitus, Expe | 1987 |
Long-term enalapril and verapamil in rats with reduced renal mass.
Topics: Animals; Enalapril; Female; Glomerulonephritis; Hypertension, Renal; Hypertrophy; Kidney; Nephrectom | 1989 |
Diabetic nephropathy in the rat: differing renal effects of an angiotensin converting enzyme inhibitor and a calcium inhibitor.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Female; | 1988 |
Effect of pharmacologic agents on the function of the hypothermically preserved dog kidney during normothermic reperfusion.
Topics: Allopurinol; Animals; Ca(2+) Mg(2+)-ATPase; Calcium-Transporting ATPases; Catalase; Cold Temperature | 1988 |
"Intact nephrons" as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy.
Topics: Animals; Glomerular Filtration Rate; Hemodynamics; Kidney Failure, Chronic; Kidney Glomerulus; Nephr | 1988 |
Verapamil in the treatment of severe postpartum hypertension.
Topics: Adult; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Pregnancy; Prospective Studies; Pro | 1988 |